← All trials
NCT04380324
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 16, 2017
- Primary completion
- Jan 20, 2019
- Completion date
- Jan 20, 2019
- First posted
- May 8, 2020
- Last posted
- May 8, 2020
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Eli LillyLead sponsor
- Eli LillyStudy director
- Nektar TherapeuticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.